Latest news with #HidradenitisSuppurativa
Zawya
3 days ago
- Business
- Zawya
Novartis and Kuwait Society of Dermatologists enter strategic partnership to advance dermatological care in Kuwait
Under the title 'United for Dermatology', the partnership will drive awareness, disease understanding, and improve the lives of patients in Kuwait diagnosed with Psoriasis, Hidradenitis Suppurativa & Chronic Spontaneous Urticaria Kuwait City, Kuwait – Novartis, a global leader in innovative medicines, signed a partnership agreement with the Kuwait Society of Dermatologists, focused on transforming dermatological care in Kuwait. This strategic partnership will prioritize high-impact immunological skin conditions such as Psoriasis, Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU) with a shared goal of bridging diagnostic gaps and improving the quality of life for patients. Together, Psoriasis, Hidradenitis Suppurativa (HS), and Chronic Spontaneous Urticaria (CSU) represent distinct chronic inflammatory skin diseases, each with unique clinical presentations and significant impact on quality of life. Beyond physical symptoms, conditions like Psoriasis, Hidradenitis Suppurativa and CSU often take a significant toll on patients' mental health, contributing to anxiety, depression and social isolation—underscoring the importance of timely, compassionate and comprehensive care. This partnership is focused on increasing education and disease awareness within the public and HCPs, in addition to evidence-driven solutions that ensure faster, more accurate diagnoses and better treatment outcomes. Dr. Atlal Allafi, President, Kuwait Society of Dermatologists, said, 'Our partnership with Novartis is focused on breaking down barriers to care. Together, we're working to empower patients to recognize symptoms earlier and support physicians in identifying these conditions sooner. By accelerating diagnosis and access to treatment, we aim to enhance patient outcomes and overall well-being.' Rabab Monir, Country Operations Head - Kuwait, Novartis, added, 'Driven by our mission to transform the future of medicine, Novartis is proud to join forces with the Kuwait Society of Dermatologists to elevate dermatological care across Kuwait. Through this collaboration, we're fostering a healthcare environment where early intervention and personalized treatment pave the way for improved patient outcomes.' A professional organization for dermatologists in Kuwait, the Kuwait Society of Dermatologists is dedicated to advancing dermatological care through education, research, and public awareness. Committed to the highest standards of medical ethics and excellence, the society plays a key role in promoting skin health across the nation. Dr Abeer Albazali, Vice President, Kuwait Society of Dermatologists, commented, 'We aim to foster collaboration among dermatologists, encouraging the exchange of knowledge and best practices that drive progress in patient care. This partnership empowers us to move from dialogue to delivery—bringing global breakthroughs to life through locally tailored solutions.' Through this collaboration, Novartis and the Kuwait Society of Dermatologists reinforce their mutual commitment to a future where patients benefit from early diagnosis, individualized care, and an improved quality of life. Disease Descriptors Chronic Spontaneous Urticaria (CSU) is a medical condition that affects 0.5-1 per cent of the global population and is characterized by chronic hives that last for six weeks or longer. These hives can appear without an obvious trigger and may cause significant itching and discomfort. Hidradenitis Suppurativa (HS) is a chronic skin condition more common in women and often undiagnosed, marked by recurrent, painful lumps or nodules under the skin. These lesions often become inflamed, can rupture, and may lead to scarring over time. Psoriasis is a chronic autoimmune skin disorder characterized by thick, red, scaly plaques on the skin. These lesions can be itchy, painful, and sometimes extensive. It is estimated that between 1 and 3 per cent of the population across countries in the Gulf are affected by this condition. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
Zawya
30-04-2025
- Health
- Zawya
Novartis and Emirates Dermatology Society renew strategic partnership to advance dermatological care in UAE
In an era of rapid medical innovation and information overload, diagnostic accuracy and clinical authenticity are crucial to eliminating delays, preventing misdiagnoses and ultimately enhancing patient outcomes Dubai, UAE – Novartis, a global leader in innovative medicines and the Emirates Dermatology Society (EDS) today announced the renewal of their partnership focused on revolutionizing dermatological care in the United Arab Emirates. Now entering its third year, the collaboration continues to prioritize high-impact immunological skin conditions such as Psoriasis, Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU) with a shared goal of closing diagnostic gaps and improving the quality of life for patients. While dermatology has made tremendous strides in the past few years, there is still an opportunity to accelerate the diagnosis and care for patients across the UAE. Beyond physical symptoms, conditions like Psoriasis, Hidradenitis Suppurativa and CSU often take a significant toll on patients' mental health, contributing to anxiety, depression and social isolation—underscoring the importance of timely, compassionate and comprehensive care. Chronic Spontaneous Urticaria (CSU) is a medical condition characterized by chronic hives that last for six weeks or longer. These hives can appear without an obvious trigger and may cause significant itching and discomfort. Hidradenitis Suppurativa (HS) is a chronic skin condition marked by recurrent, painful lumps or nodules under the skin. These lesions often become inflamed, can rupture, and may lead to scarring over time. Psoriasis is a chronic autoimmune skin disorder characterized by thick, red, scaly plaques on the skin. These lesions can be itchy, painful, and sometimes extensive. Together, Psoriasis, Hidradenitis Suppurativa (HS), and Chronic Spontaneous Urticaria (CSU) represent distinct chronic inflammatory skin diseases, each with unique clinical presentations and significant impact on quality of life. This partnership is focused on addressing these challenges with evidence-driven solutions that ensure faster, more accurate diagnoses and better treatment outcomes. 'The partnership with Novartis is about proactively addressing the barriers to care. We are committed to helping physicians recognize these conditions earlier, ensuring patients receive timely treatment and improving their overall well-being,' said Dr. Ayman Alnaeem, President, Emirates Dermatology Society. 'At Novartis, our commitment to reimagining medicine drives us to collaborate with organizations like EDS to advance dermatological care in the Gulf region. Together, we are building a healthcare ecosystem where timely, personalized care leads to better patient outcomes,' added Mohamed Ezz Eldin, Head of GCC, Novartis. The Emirates Dermatology Society (EDS) is not just a professional network—it is a leading force in shaping the future of dermatological care in the UAE. With an active management committee overseeing its activities, EDS plays a crucial role in connecting dermatologists, facilitating knowledge-sharing and promoting excellence in dermatology 'Our goal is to bring dermatologists together to collaborate, share insights and contribute to the ongoing evolution of care. This partnership allows us to turn discussions into action—translating global innovations into local solutions,' commented, Dr Raghda Al Maashari, Cultural Committee Chairperson, Emirates Dermatology Society. With this partnership, Novartis and EDS reaffirm their shared vision: a future where every patient has access to timely diagnosis, personalized treatment and a better quality of life. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
Yahoo
20-02-2025
- Health
- Yahoo
CA bill could make health insurers pay $1 million for denying care
A new bill in the California Senate could help residents fight back against denials by health insurance companies. Sen. Scott Wiener (D-San Francisco) has introduced Senate Bill 363, the Health Insurance Accountability Act, which intends to provide 'critical transparency and accountability for health insurance companies for baseless denials of coverage for medically necessary care,' Wiener's office said in a news release. 'Accountability is critical when insurance companies wrongfully deny Californians health care coverage,' said Wiener. 'The facts are alarming. Over 70% of mental health denials that make it all the way through the appeals process are overturned. This suggests insurers are engaging in widespread violations of state law and wrongfully denying urgently needed healthcare, potentially in a widespread way. We must gain a clearer picture of what is happening with coverage decisions and hold health plans accountable for unwarranted denials.' Not only would Wiener's bill require health insurance companies to 'submit a written explanation regarding claim denials and modifications and the reason for such action,' but they'd also face increasing penalties for excessive denials. Arguments over whether Luigi Mangione is a 'hero' offer a glimpse into an unusual American moment Financial penalties, which will fund children's health care services, begin at $50,000 for the first violation, $400,000 for the second and $1 million for ensuing noncompliance. Wiener's push comes after the high-profile killing of UnitedHealthcare CEO Brian Thompson, which was allegedly committed by Luigi Mangione and motivated by insurers' use of a 'deny, defend, depose' strategy to avoid covering some procedures and medications. While Wiener made no mention of Mangione, who is believed to have suffered from a back condition that may have prompted his conflict with the health insurance industry, though the highlighted others who have also struggled with having their health conditions properly covered. 'Between my own care, and that of my daughter's care, who lives with Hidradenitis Suppurativa, we've received dozens if not hundreds of denials from our health insurance plan over the years,' a woman named Colleen Henderson said in the release. 'It's ridiculous that I pay for insurance, yet they're never there when we need them. I'm grateful Senator Wiener is standing up for patients like us by requiring insurers be held accountable for their actions.' The bill is expected to be heard in its first committee in March, according to Wiener's office. The California Association of Health Plans, which represents the industry, has not yet taken a position on the bill, a spokesperson said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
